NEWS・COLUMN
We send the latest information from SMC Laboratories.
Hepatocellular Senescence Linked to Liver Cancer Development: Sirolimus Shows Preventive Potential in Preclinical Study
A new study published in Human Cell by researchers at the University of Nottingham highlights the role of hepa…
IL-18 Binding Protein Shows Promise in Suppressing Fibrosis in MASH: New Study Published in Cell Reports Medicine
A recent study published in Cell Reports Medicine (April 2025) reports that treatment with an IL-18 binding pr…
Devonian Reports Positive Results in MASH Liver Study
In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of con…
New possibilities for MASH treatment: Confirmation of the effectiveness of 2-hydroxybenzylamine
A new study published in the Feb 2025 issue of Nutrients highlights the therapeutic promise of 2-hydroxybenzyl…
CytoDyn Reports Significant Fibrosis Reversal in SMC Lab Studies
In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstratin…
A New Approach to Pulmonary Fibrosis Research: Introducing SMC Laboratories’ IPF Model
SMC Laboratories, Inc. (Tokyo, Japan) is a preclinical CRO specializing in pharmacological evaluations using d…
Chitinase-1 Inhibition Attenuates MASH Progression: A Novel Therapeutic Approach via Metabolic Reprogramming
In May 2025, a collaborative research team from OncoArendi Therapeutics and academic institutions in Poland pu…
Case study: Study published in Periodontitis promotes hepatocellular carcinoma Stelic Animal model mice.
We introduce a case study of basic research using our MASH model (STAM™ model). It has been reported th…
CytoDyn has published a press release regarding the leronlimab efficacy preclinical study for MASH/fibrosis provided by SMC
CytoDyn Inc., which is our client, has announced the results of pharmacology study using a STAM™ mouse model. …
Case study: Study published in Clinical and Translational Science on the effects of adiponectin-derived peptide ALY688 in MASH/liver fibrosis of STAM model.
We introduce a case study of pharmacology study of adiponectin-derived peptide ALY688 using our MASH model (ST…
Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~
Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (Nove…
Case study: Study published in Nature Biotechnology on the effects of TNIK inhibitor in lung and kidney fibrosis models.
We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and af…